Navigation Links
PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final
Date:2/28/2011

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that the Technical Board of Appeal of the European Patent Office (EPO) has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's  European Patent No. 0 451 216B (the '216B Patent) overturned and the patent revoked. The effect of the termination of the opposition appeal proceeding is that the 2007 EPO decision upholding the claims of PDL's '216B Patent as valid will become the final decision of the EPO. The hearing was scheduled for February 28 and March 1, 2011.  In the year ended December 31, 2010, approximately 35 percent of PDL's revenues were derived from sales of products that were made in Europe and sold outside of the United States. These revenues could have been negatively impacted or eliminated entirely by an adverse ruling at the hearing.  

In an opposition proceeding brought by multiple parties, the Opposition Division of the EPO found in 2007 the claims of the '216B Patent to be valid. Five of the opposing parties filed notices of appeal to the Technical Board of Appeal of the EPO seeking to have the decision of the Opposition Division upholding the '216B Patent overturned and the patent revoked. Three of those parties filed detailed grounds of appeal:  UCB Pharma S.A., BioTransplant Incorporated whose counsel PDL believes has been financially supported by MedImmune LLC, and Novartis AG. Pursuant to PDL's recent settlements with UCB, MedImmune and Novartis, which were previously announced, and as a result of PDL's recent acquisition of BioTransplant out of bankruptcy and subsequent withdrawal of their appeal, all of the active appellants have formally withdrawn their participation in the appeal proceeding. Accordingly, the EPO cancelled the appeal hearing, terminated the opposition proceeding and all appeals thereof in their entirety.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PDL BioPharma Announces Regular Quarterly Dividend Policy
2. PDL BioPharma to Present at Upcoming Conferences
3. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
4. Success Factors and Failure Points in Biopharmaceutical Product Launches
5. Plato BioPharma, Inc Appoints New Board Member
6. UCB and PDL BioPharma Resolve Patent Disputes
7. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
8. Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
9. PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
10. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
11. Genesis Biopharma to Present at 2011 Biotech Showcase Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, deadbolts are ... getting a guard dog or having an alarm system installed. But unless there is ... entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: “In the ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... By scoring ... its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's ... top 1% of all charities reviewed by Charity Navigator and earns ANRF a spot ...
(Date:6/23/2017)... Va. (PRWEB) , ... June 23, 2017 , ... The ... the president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. ... Veterans Affairs. , Bowman brings an intimacy with the issues and challenges ...
(Date:6/23/2017)... New York, NY (PRWEB) , ... June 23, 2017 , ... ... prefer to watch it while others prefer to read it, and some people don't ... printed versus visual pornography. Here's what they found: , Erotic literature can give readers ...
(Date:6/23/2017)... D.C. (PRWEB) , ... June 23, 2017 , ... ... during cooking is essential, and two new videos highlight the importance of correctly ... Specialist Christine Bruhn, Ph.D., who has done extensive research on consumer food safety ...
Breaking Medicine News(10 mins):